Recombinant Afamin/Wnt3a

MBL Life Sciences

Catalog No.: MBL-J2-002

High-Purity, Stabilized Wnt3a for Reliable Organoid and Stem Cell Culture

Recombinant Afamin/Wnt3a is a stabilized, bioactive complex of mouse Wnt3a and human Afamin, designed to overcome the solubility and stability limitations of conventional Wnt3a proteins in serum-free systems. This ready-to-use recombinant formulation enables consistent Wnt pathway activation for demanding applications in organoid culture, stem cell maintenance, and Wnt signaling research.

Key Benefits

• Enhanced Solubility & Stability – Afamin prevents Wnt3a aggregation, preserving bioactivity in defined media
• Functionally Active & High Purity – 90% pure recombinant protein complex, verified by SDS-PAGE
• Ready for Experimental Use – Supplied in Tris-HCl buffer with no need for pre-conditioning or serum
• Recombinantly Expressed in CHO-K1 Cells – PA-tagged Wnt3a (~41 kDa) and Myc-tagged Afamin (~70 kDa) for traceability
• Flexible for Small-Scale or Pilot Studies – 60 µg total protein (300 µL) in a convenient liquid format

Applications

• Organoid generation from digestive tissues
• Long-term Lgr5+ stem cell culture
• Canonical Wnt signaling pathway studies in vitro

Storage & Handling

Store at –20°C or below. To maintain activity after dilution, use PBS with 0.04% HSA or BSA and avoid repeated freeze–thaw cycles.

Note: Some applications may be subject to third-party patents. Please consult your institution’s IP office for guidance.

References

1. Mihara, E., Matano, M., Yamamoto, H., Sato, T., & Takagi, J. (2016). Active and water-soluble form of lipidated Wnt protein is maintained by a serum glycoprotein Afamin/α-albumin. eLife, 5, e11621. [PMID: 26902720]
2. Nanki, K., Toshimitsu, K., Takano, A., Fujii, M., & Sato, T. (2018). Divergent routes toward Wnt and R-spondin niche independency during human gastric carcinogenesis. Cell, 174(4), 856–869.e17. [PMID: 30096312]
3. Sugimoto, S., Ohta, Y., Fujii, M., et al. (2018). Reconstruction of the human colon epithelium in vivo. Cell Stem Cell, 22(2), 171–176.e5. [PMID: 29290616]
4. Seino, T., Kawasaki, S., Shimokawa, M., et al. (2018). Human pancreatic tumor organoids reveal loss of stem cell niche factor dependence during disease progression. Cell Stem Cell, 22(3), 454–467.e6. [PMID: 29337182]
5. Sugimoto, S., Sato, T. (2020). Organoid derivation and orthotopic xenotransplantation for studying human intestinal stem cell dynamics. Methods in Molecular Biology, 2171, 229–239. [PMID: 32705652]
6. Nanki, K., Fujii, M., Shimokawa, M., et al. (2020). Somatic inflammatory gene mutations in human ulcerative colitis epithelium. Nature, 577(7789), 254–259. [PMID: 31853059]
7. Sasaki, N., Miyoshi, N., Fujii, M., et al. (2020). Development of a scalable coculture system for gut anaerobes and human colon epithelium. Gastroenterology, 159(2), 388–390.e5. [PMID: 32199883]
8. Mae, S., Kishimoto, T., Mochizuki, Y., et al. (2020). Expansion of human iPSC-derived ureteric bud organoids with repeated branching potential. Cell Reports, 32(4), 107963. [PMID: 32726627]
9. Nanki, Y., Chiyoda, T., Hirasawa, A., et al. (2020). Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumors applicable for drug sensitivity and resistance testing. Scientific Reports, 10, 12503. [PMID: 32724113]
10. Miyabayashi, K., Baker, L.A., Deschênes, A., et al. (2020). Intraductal transplantation models of human pancreatic ductal adenocarcinoma reveal progressive transition of molecular subtypes. Cancer Discovery, 10(10), 1566–1589. [PMID: 32703770]

Product Specifications

• Application: Cell Culture
• Endotoxin Levels: < 1.0 EU/mL by the LAL assay
• Purity: Greater than 90% purity as confirmed on SDS-PAGE
• Formulation: 60 ug in 300 uL volume of 20 mM Tris-HCI (pH 7.4), 150 mM NaCI